← Leaderboards
James F Kronauge
Molecular Insight Pharmaceuticals, Inc.
$10,765,400
Attributed
$11,765,400
Total exposure
9
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,765,400 · 9
By mechanism
R44$9,354,916 · 6
U44$2,000,000 · 1
R43$410,484 · 2
Top collaborators
- Xiufang Guo1 shared
- James J Hickman1 shared
Most similar at Molecular Insight Pharmaceuticals, Inc.
Same institution · by research overlap
- Kevin P Maresca$402,626
Others in their field
Top investigators on “Dose”
- Lawrence Corey · Fred Hutchinson Cancer Center$251,944,397
- Sharon A Nachman · Johns Hopkins University$213,337,729
- David Heimbrook · Leidos Biomedical Research, Inc.$146,807,554
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$134,297,561
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$124,321,134
- Peter C Adamson · National Childhood Cancer Foundation$122,197,823
Research focus
DoseSmall Business Innovation Research GrantValidationPharmaceutical PreparationsCellsProductionSafetyRattusReportingLabelTumorTissuesScale UpImageRadiolabeledMonitorPre-ClinicalRadiopharmaceuticalsProdrugsClinical ResearchAnimalsAnalytical MethodClinical TrialsInsight
Grant awards (21)
Human NeuromuscularJunction Platform to Evaluate Botulinum Toxin Potency$1,000,000
U44 · FY2025 · TR · contact PI
Human NeuromuscularJunction Platform to Evaluate Botulinum Toxin Potency$1,000,000
U44 · FY2024 · TR · contact PI
Clinical Translation of a Novel Diagnostic Agent to Predict Immunotherapy Response in Solid Tumors$774,682
R44 · FY2020 · CA · contact PI
Clinical Translation of a Novel Diagnostic Agent to Predict Immunotherapy Response in Solid Tumors$759,285
R44 · FY2019 · CA · contact PI
Clinical Translation of a Novel Diagnostic Agent to Predict Immunotherapy Response in Solid Tumors$264,066
R44 · FY2018 · CA · contact PI
A kit based PET agent: edotreotide Ga 68 for clinical imaging of somatostatin rec$956,175
R44 · FY2014 · CA · contact PI
A kit based PET agent: edotreotide Ga 68 for clinical imaging of somatostatin rec$542,102
R44 · FY2012 · CA · contact PI
A kit based PET agent: edotreotide Ga 68 for clinical imaging of somatostatin rec$437,398
R44 · FY2012 · CA · contact PI
Systemic radiotherapy for metastatic melanomas: Innovation of a novel radiopharma$722,670
R44 · FY2011 · CA · contact PI
Development of a Molecular Targeting Agent for PSMA to Diagnose Metastatic Prosta$327,410
R44 · FY2011 · CA · contact PI
Development of a Molecular Targeting Agent for PSMA to Diagnose Metastatic Prosta$801,864
R44 · FY2010 · CA · contact PI
Development of a kit based PET molecular imaging agent: edotreotide Ga 68 for so$262,993
R43 · FY2010 · CA · contact PI
Systemic radiotherapy for metastatic melanomas: Innovation of a novel radiopharma$911,810
R44 · FY2009 · CA · contact PI
Nanodosing: A path to higher sensitivity and lower toxicity pharmaceuticals$496,373
R44 · FY2009 · CA · contact PI
Development of a Molecular Targeting Agent for PSMA to Diagnose Metastatic Prosta$488,453
R44 · FY2009 · CA · contact PI
Nanodosing: A path to higher sensitivity and lower toxicity pharmaceuticals$485,175
R44 · FY2008 · CA · contact PI
Systemic radiotherapy for metastatic melanomas: Innovation of a novel radiopharma$331,449
R44 · FY2008 · CA · contact PI
Developing Nanodosing of Iobenguane I 131 for Radiotherapy$351,359
R44 · FY2007 · CA · contact PI
Nanodosing: A path to higher sensitivity and lower toxicity pharmaceuticals$130,761
R44 · FY2007 · CA · contact PI
Developing Nanodosing of Iobenguane I 131 for Radiotherapy$573,884
R44 · FY2006 · CA · contact PI
High sensitivity and low toxicity radiopharmaceuticals$147,491
R43 · FY2005 · CA